An observational study in Chronic Pancreatitis, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by NYU Langone Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Pancreatitis, Chronic with a site in United States — 27 open to participants now, 38 under way, none of them phase 3. Pancreatitis, Chronic · United States.
Among the 111 studies in Pancreatitis, Chronic with a site in United States, this one is the 36th largest by enrollment of the 38 observational ones that give a count, is one of 5 that started in 2023, is one of 38 observational ones, reaches primary completion later than 13 of the 37 other live ones, and was the 92nd registered.
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
Browse Pancreatitis, Chronic studies →27 of the 111 studies in Pancreatitis, Chronic with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Orlando Health, Inc. · Sites in United States
Ages 18+
Anna Evans Phillips · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 15 · Phase 3 7 · Phase 4 6
First in 2000; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 300 across 117 observational studies indexed under Pancreatitis, Chronic.
Median enrollment 32 across the 73 interventional studies, 167 across the 38 observational. Of the 63 that completed or were terminated, 23 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 111 have an industry lead sponsor. The 10 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 1 study filed under Pancreatitis, Chronic — fewer than ten, so there is no comparison to draw.
16 of the studies in Pancreatitis, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03097185Baylor Research InstituteAnalysis of Graft Function Following Autologous Islet Transplantation | 2026-12 |
| NCT07174609Johns Hopkins UniversityScrambler Therapy in Chronic Pancreatitis | 2026-12-01 |
| NCT05925036VA Office of Research and DevelopmentNovel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis | 2026-12-31 |
| NCT06651580M.D. Anderson Cancer CenterBiospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | 2027-02-02 |
| NCT07285863Mayo ClinicA Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects | 2027-03 |
Add all 16 to your calendar (.ics) → With an account.
Among the 111 studies in Pancreatitis, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational prospective study to develop predictive biomarkers for pain response in participants with chronic pancreatitis scheduled for endoscopic therapy. Participants will undergo baseline assessments including electroencephalography (EEG), quantitative sensory testing (QST), and psychosocial questionnaires. Response to endoscopic therapy will be assessed at approximately 3, 6, 12 and 18 months post-procedure using questionnaires.
Adults older than 18 years with painful chronic pancreatitis scheduled for endoscopic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic pancreatitis scheduled for endoscopic therapy will undergo baseline assessments including EEG, quantitative sensory testing, and psychosocial questionnaires. Follow-up questionnaires will be completed at approximately 3, 6, 12 and 18 months post-procedure.
Change from Baseline in Brief Pain Inventory (BPI) Score at Month 3 Post-Operation
BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.
Time frame: Baseline, Month 3 Post-Operation
Change from Baseline in BPI Score at Month 6 Post-Operation
BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.
Time frame: Baseline, Month 6 Post-Operation
Change from Baseline in BPI Score at Month 12 Post-Operation
BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.
Time frame: Baseline, Month 12 Post-Operation
Change from Baseline in BPI Score at Month 18 Post-Operation
BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.
Time frame: Baseline, Month 18 Post-Operation
Change from Baseline in Patient Reported Outcome System (PROMIS) - Physical Function - Short Form 6b Score at Month 3 Post-Operation
The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.
Time frame: Baseline, Month 3 Post-Operation
Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 6 Post-Operation
The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.
Time frame: Baseline, Month 6 Post-Operation
Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 12 Post-Operation
The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.
Time frame: Baseline, Month 12 Post-Operation
Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 18 Post-Operation
The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.
Time frame: Baseline, Month 18 Post-Operation
Number of Participants who use Opioids at Baseline
Time frame: Baseline
Number of Participants who use Opioids at Month 3
Time frame: Month 3
Number of Participants who use Opioids at Month 6
Time frame: Month 6
Number of Participants who use Opioids at Month 12
Time frame: Month 12
Number of Participants who use Opioids at Month 18
Time frame: Month 18
Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 3 Post-Procedure
The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 6 Post-Procedure
The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 12 Post-Procedure
The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 18 Post-Procedure
The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 3 Post-Procedure
The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 6 Post-Procedure
The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 12 Post-Procedure
The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 18 Post-Procedure
The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 3 Post-Procedure
The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 6 Post-Procedure
The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 12 Post-Procedure
The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 18 Post-Procedure
The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 3 Post-Procedure
The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 6 Post-Procedure
The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 12 Post-Procedure
The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 18 Post-Procedure
The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 3 Post-Procedure
The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 6 Post-Procedure
The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 12 Post-Procedure
The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 18 Post-Procedure
The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Pain Catastrophizing Scale (PCS) Score at Month 3 Post-Procedure
The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PCS Score at Month 6 Post-Procedure
The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PCS Score at Month 12 Post-Procedure
The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PCS Score at Month 18 Post-Procedure
The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Sleep Duration at Month 3 Post-Procedure
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in Sleep Duration at Month 6 Post-Procedure
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in Sleep Duration at Month 12 Post-Procedure
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in Sleep Duration at Month 18 Post-Procedure
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Score at Month 3 Post-Procedure
TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in TAPS Score at Month 6 Post-Procedure
TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in TAPS Score at Month 12 Post-Procedure
TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in TAPS Score at Month 18 Post-Procedure
TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Patient Global Impression of Change (PGIC) Score at Month 3 Post-Procedure
PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PGIC Score at Month 6 Post-Procedure
PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PGIC Score at Month 12 Post-Procedure
PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PGIC Score at Month 18 Post-Procedure
PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Patient Health Questionnaire-2 (PHQ-2) Score at Month 3 Post-Procedure
PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PHQ-2 Score at Month 6 Post-Procedure
PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PHQ-2 Score at Month 12 Post-Procedure
PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PHQ-2 Score at Month 18 Post-Procedure
PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Generalized Anxiety Disorder 2 (GAD-2) Score at Month 3 Post-Procedure
GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in GAD-2 Score at Month 6 Post-Procedure
GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in GAD-2 Score at Month 12 Post-Procedure
GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in GAD-2 Score at Month 18 Post-Procedure
GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.
Time frame: Baseline, Month 18 Post-Procedure
Change from Baseline in Pain, Enjoyment of Life and General Activity (PEG) Scale at Month 3 Post-Procedure
PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.
Time frame: Baseline, Month 3 Post-Procedure
Change from Baseline in PEG Scale at Month 6 Post-Procedure
PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.
Time frame: Baseline, Month 6 Post-Procedure
Change from Baseline in PEG Scale at Month 12 Post-Procedure
PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.
Time frame: Baseline, Month 12 Post-Procedure
Change from Baseline in PEG Scale at Month 18 Post-Procedure
PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.
Time frame: Baseline, Month 18 Post-Procedure
Plan to share: Yes — As an NIH-HEAL initiative sponsored study, our IPD sharing comply with the Helping to End Addiction Long-term (HEAL) Public Access and Data Sharing Policy. The de-identified participant data will be shared and deposited into the National Institute of Mental Health Data Archive (NIMH) Data Archive (NDA). The NDA provides metadata, study digital object identifier (DOI), and long-term access. This repository is supported by several institutes and centers at the NIH, and datasets are available through a request process. Investigators requesting data must be affiliated with an NIH-recognized research institution that maintains an active Federalwide Assurance (FWA), and complete and submit a Data Use Certification approved by an authorized institutional business official with signature authority. This request will then be reviewed by the NDA Data Access Committee.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Lisa.Doan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for May 2027, 41 months after the start.
Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 41 months is below that.
Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Mar 2027 → May 2027 and completion Jun 2028 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.